Compound News and Research

RSS

Nano-emulsion shows promise for Viagra patch

Sildenafil citrate, commonly known as Viagra, is currently the first choice drug for erectile dysfunction but despite its success oral delivery of the drug is hampered by numerous side effects, the long delay before it starts working and the short amount of time it lasts. Researchers in Egypt think they may have a solution via nanotechnology.

27 Jul 2011

Lipid-based nanocarrier can improve cancer treatments

Scientists seeking to improve cancer treatments have created a tiny drug transporter that maximizes its ability to silence damaging genes by finding the equivalent of an expressway into a target cell.

27 Jul 2011

NeurOp receives NIH grant to support research program for ischemia

NeurOp, Inc., a biopharmaceutical company developing new treatments for central nervous system disorders, today announced that the National Institutes of Health (NIH) has awarded the company a $3 million grant to support its research program for ischemia.

27 Jul 2011

Anavex presents data on neuroprotective evidence for lead compound for Alzheimer’s

Anavex Life Sciences Corp. is pleased to provide a summary of its second poster presentation at the Alzheimer’s Association International Conference (AAIC) held in Paris, entitled “Preclinical development of new tetrahydrofuran derivatives targeting the sigma-1 chaperone protein as neuroprotectants in Alzheimer’s disease.”

26 Jul 2011

New hope for infants born with Spinal Muscular Atrophy

Researchers in Ottawa report new hope for the treatment of infants born with serious genetic disorder.

26 Jul 2011

EMA recommends orphan drug designation for 4SC's resminostat to treat HCC

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced that the European Medicines Agency (EMA) has recommended resminostat for designation as orphan medicinal product for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.

26 Jul 2011

R-Tech Ueno announces protocol amendment of RK-023 Phase I trial for eyelash hypotrichosis

R-Tech Ueno is pleased to announce protocol amendment of a Phase I Clinical Study of RK-023, a new compound being developed for the treatment of hypotrichosis of the eyelashes.

25 Jul 2011

A*STAR's ETC, Agilent introduce drug screening platform

Agilent Technologies Inc. and A*STAR's Experimental Therapeutics Centre (ETC) today announced the launch of a drug screening platform within ETC's new Singapore Screening Centre.

22 Jul 2011

Adamis receives U.S. patent for APC-100 to treat prostate cancer

Adamis Pharmaceuticals Corporation, today announced the technology which constitutes its compound APC-100 was recently granted a patent in the United States.

22 Jul 2011

Australian anti-cancer company completes $2.6 million placement

Australian monoclonal antibody company, Immune System Therapeutics Limited (IST), today said it completed a private placement to raise $2 million from new and existing private and institutional investors in Australia. Investors have agreed to purchase 5,200,000 shares in the company at a price of $0.50 cents per share resulting in gross proceeds of $2.6 million.

21 Jul 2011

Pharmaceutical waste forms a whole new range of contaminants

The health implications of polluting the environment weigh increasingly on our public consciousness, and pharmaceutical wastes continue to be a main culprit. Now a Tel Aviv University researcher says that current testing for these dangerous contaminants isn't going far enough.

21 Jul 2011

Experts to explore wound healing abilities of dolphins

A Georgetown University Medical Center (GUMC) scientist who has previously discovered antimicrobial compounds in the skin of frogs and in the dogfish shark has now turned his attention to the remarkable wound healing abilities of dolphins.

21 Jul 2011

Three flutemetamol clinical abstracts to be presented at 2011 Alzheimer's Association ICAD

Recent clinical research data reported that the investigational amyloid imaging agent [18F]Flutemetamol showed highly consistent image interpretation1 and showed comparable in vitro binding to the Pittsburgh Compound-B investigational imaging agent3.

21 Jul 2011

Investigational compound dapagliflozin receives negative recommendation from FDA Advisory Committee

Bristol-Myers Squibb Company and AstraZeneca today reported the outcome of the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee meeting on the New Drug Application for the investigational compound dapagliflozin.

20 Jul 2011

Valeant, sanofi-aventis partner to market and distribute Zuacta cream

Valeant Pharmaceuticals International, Inc. announced today that its subsidiary, Valeant International SRL, has entered into an agreement with sanofi-aventis Canada Inc.

20 Jul 2011

Aeterna's AEZS-108 final Phase 2 results in endometrial cancer to be presented at ESGO 2011

Aeterna Zentaris Inc. today announced that final Phase 2 results in endometrial cancer on its anticancer compound, AEZS-108, will be presented during a poster session at the upcoming 17th International Meeting of the European Society of Gynaecological Oncology, to be held September 11-14, 2011, at the Milan Convention Center in Milan, Italy.

19 Jul 2011

Sofinnova Ventures leads $44 million Series B private equity financing for SARcode Bioscience

SARcode Bioscience, Inc., a privately-held biopharmaceutical company, announced today the completion of a $44 million Series B private equity financing. The financing round was led by Sofinnova Ventures and was augmented by the additional backing of Rho Ventures and existing investors Alta Partners and Clarus Venture Partners.

18 Jul 2011

Novel compound blocks signaling from protein implicated in many types of cancer

Researchers at New York University's Department of Chemistry and NYU Langone Medical Center have developed a compound that blocks signaling from a protein implicated in many types of cancer. The compound is described in the latest issue of the journal Nature Chemical Biology.

18 Jul 2011

Global research initiatives to standardize Alzheimer's biomarkers

As the Alzheimer's field moves closer to new and earlier tests for the disease, innovative global research initiatives are taking the first important steps to standardize Alzheimer's biomarkers, as evidenced by two presentations made today at the Alzheimer's Association(R) International Conference 2011 (AAIC 2011) in Paris.

18 Jul 2011

Higher rates of falls can occur very early in Alzheimer's disease

Falls are more common among individuals with the earliest signs of Alzheimer's, according to a study presented at the Alzheimer's Association® International Conference 2011.

18 Jul 2011